Alkermes plc $ALKS Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA trimmed its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 4.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,759,080 shares of the company’s stock after selling 143,430 shares during the period. Primecap Management Co. CA’s holdings in Alkermes were worth $82,772,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Norges Bank acquired a new position in Alkermes during the second quarter worth $53,326,000. BNP Paribas Financial Markets boosted its position in shares of Alkermes by 787.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock worth $32,486,000 after purchasing an additional 1,007,488 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Alkermes during the 3rd quarter worth $27,040,000. Holocene Advisors LP grew its stake in shares of Alkermes by 31.2% during the 2nd quarter. Holocene Advisors LP now owns 2,853,768 shares of the company’s stock worth $81,646,000 after purchasing an additional 679,166 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Alkermes by 43.0% in the 2nd quarter. Bank of America Corp DE now owns 2,155,087 shares of the company’s stock valued at $61,657,000 after purchasing an additional 647,905 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on ALKS. HC Wainwright reissued a “neutral” rating and set a $43.00 price objective on shares of Alkermes in a report on Thursday. Deutsche Bank Aktiengesellschaft decreased their price target on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Weiss Ratings restated a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Wells Fargo & Company lifted their price objective on Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Bank of America boosted their target price on Alkermes from $33.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Price Performance

Shares of Alkermes stock opened at $30.73 on Friday. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.32. The business has a 50 day moving average price of $31.50 and a 200 day moving average price of $30.18. The company has a market capitalization of $5.07 billion, a P/E ratio of 21.49 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million for the quarter, compared to analysts’ expectations of $380.44 million. During the same period in the previous year, the business posted $1.05 EPS. The business’s quarterly revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, research analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Insider Transactions at Alkermes

In related news, Director Shane Cooke sold 61,200 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director owned 103,744 shares of the company’s stock, valued at approximately $3,586,430.08. The trade was a 37.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the completion of the transaction, the executive vice president owned 57,740 shares in the company, valued at approximately $1,959,118.20. This trade represents a 13.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 148,148 shares of company stock valued at $5,028,378. 4.40% of the stock is currently owned by company insiders.

Key Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Brokerage bullishness — Wolfe Research initiated coverage with an “outperform” and a $45 price target, and Wells Fargo raised its target to $43 with an “overweight” rating; both signal analyst conviction on upside potential. Wolfe Research initiation Wells Fargo target raise
• Neutral Sentiment: Top-line mostly in line — Q4 revenue (~$384.6M) was roughly in-line/just above consensus, which reduces immediate fundamental concern on sales. Company press release / slide deck
• Neutral Sentiment: Analyst divergence — RBC nudged its price target down (from $47 to $45) but maintained an “outperform” view, reflecting continued upside in estimates despite some analyst calibration. RBC note
• Neutral Sentiment: Short-interest data appears unreliable — recent feeds show zero shares reported and a 0.0 days ratio, suggesting reporting errors rather than a real short-squeeze signal. (Watch for cleaned data in coming days.)
• Negative Sentiment: Profitability miss and weak EPS outlook — Alkermes reported EPS below consensus (company-stated ~$0.29 vs. ~$0.43 expected) and issued FY2026 EPS guidance of roughly -0.80 to -0.68, a sharp downgrade versus street expectations; that swing in earnings outlook is the primary negative driver. Q4 results & guidance
• Negative Sentiment: CEO succession / leadership change created near-term uncertainty — the company announced Richard Pops will retire as CEO on July 31, 2026 with Blair Jackson named successor; the market reacted negatively to the combination of leadership transition and the earnings/guidance news. CEO succession press release Market reaction coverage

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.